Active, not recruitingNot applicableNCT04476862
Cerliponase Alfa Observational Study in the US
Studying Late infantile CLN2 disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- BioMarin Pharmaceutical
- Principal Investigator
- Medical Director, MDBioMarin Pharmaceutical
- Intervention
- Cerliponase Alfa(drug)
- Enrollment
- 35 enrolled
- Eligibility
- All sexes
- Timeline
- 2020 – 2030
Study locations (16)
- Arkansas Children's Hospital, Little Rock, Arkansas, United States
- Children's Hospital of Orange County, Orange, California, United States
- Children's Hospital of Colorado, Aurora, Colorado, United States
- Children's National Hospital, Washington D.C., District of Columbia, United States
- Advent Health, Orlando, Florida, United States
- Children's Healthcare of Atlanta, Atlanta, Georgia, United States
- Rush University Medical Center, Chicago, Illinois, United States
- Boston Children's Hospital,, Boston, Massachusetts, United States
- Children's Hospital Minnesota, Minneapolis, Minnesota, United States
- NYU Langone Medical Center, New York, New York, United States
- Mt. Sinai School of Medicine, New York, New York, United States
- University of Rochester Medical Center, Rochester, New York, United States
- Nationwide Children's Hospital, Columbus, Ohio, United States
- University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
- Texas Children's Hospital, Houston, Texas, United States
- +1 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04476862 on ClinicalTrials.gov